Last updated: June 2026. The compounds discussed below are prescription or compounded products, and several are not approved by the FDA for the uses men over 40 are chasing. Every regulatory and clinical claim below is sourced, and readers are encouraged to check the primary references themselves.
A reader recently posed a question that sounds simple and turns out not to be: are the peptides advertised online, sermorelin, BPC-157, and the rest, legal to buy and use? The honest answer is that “legal” is doing three different jobs in that sentence, and most of the confusion around these products comes from treating it as one job instead of three. It helps to think of it as three separate ledgers, each with its own rules, and a man can be clear in one ledger while being exposed in another.
The first ledger: legal to sell
Research-chemical websites sell peptides labeled “for research use only” or “not for human consumption.” That label is not boilerplate. It is the legal foundation the sale rests on. A chemical marketed for laboratory research occupies a different regulatory category than a drug marketed for a person to use. Once a product is sold and promoted for a man to inject for recovery or anti-aging purposes, it becomes, in regulatory terms, an unapproved new drug, and that is a far more heavily governed category.
So the sale itself can be technically lawful precisely because the label insists the buyer is a researcher and the vial is destined for a beaker. The purchaser’s own use of the product steps outside the frame that made the transaction legal in the first place. The disclaimer protects the seller. It does not protect the person holding the syringe.
The second ledger: legal to use
This is where the regulatory picture gets genuinely unsettled, and where it shifts month to month rather than staying fixed.
BPC-157 is the case study. The FDA had placed it on its Category 2 “do not compound” list, reserved for substances presenting significant safety concerns. In April 2026, the agency removed BPC-157 from that list, along with eleven other peptides, after the original nominations were withdrawn. A Pharmacy Compounding Advisory Committee meeting is scheduled for July 23 to 24, 2026, to consider whether these substances belong on the approved 503A bulk-substances list [1]. That is a meaningfully different thing from approval. Removal from a do-not-compound list moves a substance out of one category and into an evaluative holding pattern, pending a committee that has not yet ruled. The distance between “no longer flagged as a problem” and “approved and shown to be safe” is considerable, and marketing language tends to blur it.
The science underneath that regulatory limbo is thin on its own terms. A systematic review in the Hospital for Special Surgery’s journal describes the BPC-157 evidence base as almost entirely preclinical, drawn from animal and cell studies, with no clinical safety data in humans and no FDA-approved indication [2]. So there are two separate problems stacked on top of each other: an unsettled legal status, and an evidence base that has not yet reached human trials.
Growth-hormone peptides such as sermorelin, CJC-1295, and ipamorelin occupy still another position. They are not typically sold as approved finished drugs for anti-aging use. Where they exist legally, it is as compounded preparations, prescribed by a licensed clinician and compounded by a licensed pharmacy under recognized standards. The pharmacology behind CJC-1295’s ability to prolong growth hormone and IGF-1 secretion in healthy adults has been documented in the endocrinology literature [6]. Buy the identical molecule as a “research use only” powder online, however, and it reverts to the unapproved-new-drug problem described above. Same molecule, entirely different legal footing, depending on whether a prescriber and a pharmacy stand behind it.
The third ledger: legal to compete on
This is the ledger most men do not think to check, and it can end an amateur career as decisively as any injury.
Under the 2026 WADA Prohibited List, peptide hormones, growth factors, and growth-hormone secretagogues are classified under S2 and prohibited in sport [3]. That sweeps in sermorelin, CJC-1295, ipamorelin, and the broader growth-hormone-releasing family, and testosterone is prohibited as well. A “research use only” label offers a tested athlete no protection whatsoever. A prohibited substance remains prohibited regardless of what the bottle says or how it was obtained. The masters triathlete, the amateur powerlifter in a tested federation, the weekend competitor who assumes the rules apply only to professionals, all of them can be in entirely legal possession of a compound that is nonetheless barred from the competition they intend to enter.
Three ledgers, three separate answers, and a man can be clean in the first, exposed in the second, and disqualified in the third, all with the same vial.
Testosterone as the instructive comparison
Testosterone is worth setting apart because it shows what a mature regulatory and evidence framework actually looks like. It is an FDA-approved drug, legal to prescribe and dispense through a pharmacy, and it has serious human data behind it. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, randomized 5,246 middle-aged and older men with diagnosed low testosterone and cardiovascular risk. Testosterone did not raise major adverse cardiac events compared with placebo, though the trial also reported more cases of atrial fibrillation in the testosterone group, a finding the authors did not obscure [4]. That combination, thousands of participants, a clear benefit finding, and an honestly reported risk, is what a compound with a real evidentiary foundation looks like.
Even testosterone comes with conditions, and the conditions are the point rather than an inconvenience. It requires diagnosis, dosing decisions, and monitoring, which is why it is a prescription medicine. The adjunct drugs sometimes used alongside it, HCG, enclomiphene, anastrozole, are prescription medicines too, because managing testosterone’s downstream effects is itself a clinical task [5]. The broader lesson from the FDA’s approach to receptor-agonist and hormone therapies generally is that boxed warnings and prescribing oversight exist because these are not products meant to be self-managed from a research-chemical cart [5].
Where a supervised path actually sits
Put the three ledgers together and a pattern emerges: legality that holds up under scrutiny is legality built on a clinical relationship, not on a disclaimer. A licensed clinician evaluates a patient and prescribes when appropriate; a licensed, accredited pharmacy compounds and dispenses. That structure, not the “not for human use” label, is what makes legal use legal in any durable sense.
Among the options that route a patient through that structure, with an actual prescriber and an actual pharmacy rather than a research-chemical storefront, FormBlends operates as a physician-supervised telehealth provider. Nothing here is a recommendation to purchase anything from FormBlends or from any other seller, and there is no product or checkout being pointed to. It is simply the clearest illustration, among the paths reviewed for this piece, of what supervised access looks like: a named clinician, a named pharmacy, and a record that exists if something needs to be checked later. That is a meaningfully different proposition from a vial that arrives with no one’s name attached to it at all.
Honest questions and honest answers
Are peptides safe for men over 40? It depends heavily on which peptide, at what dose, and from what source. Some peptides carry reasonable human safety data from actual clinical trials; many others have only been studied in rodents or in cell cultures. The largest practical risk for a man over 40 is often not the peptide’s inherent pharmacology but the unregulated source it comes from, since independent lab testing of gray-market vials has repeatedly turned up wrong concentrations, contaminants, or the wrong compound altogether. A prescription obtained through physician supervision is the only route with meaningful accountability behind it.
Do peptides actually work, or is this mostly marketing? Some do, for specific and fairly narrow purposes. PT-141 carries FDA approval for a sexual dysfunction indication. Certain GLP-1 peptides have strong clinical trial support for metabolic outcomes. Growth hormone secretagogues like ipamorelin show measurable effects on GH pulsing in small human studies, though long-term data on healthy aging outcomes in men remains sparse. The evidence varies enormously by compound, and the anti-aging marketing around several of these products runs well ahead of what published trials currently show.
What peptides do men over 40 most often bring up with a doctor? BPC-157 for joint and tissue recovery, ipamorelin or CJC-1295 for growth hormone support, PT-141 for libido, and TB-500 for injury healing come up most often. Of these, only PT-141 carries full FDA approval in the US. The rest occupy a gray zone: available through compounding pharmacies operating under physician oversight, such as FormBlends, or through research-chemical vendors with no accountability to the person actually using the product.
Where can men legally buy peptides in the United States? As the sections above make clear, the picture is genuinely layered rather than simple. The clearest legal path is a prescription from a licensed physician, filled by an accredited compounding pharmacy. Peptides sold online under a “research use only” label sit in a regulatory gray area the FDA has been steadily narrowing, and those products come with no guarantee of purity or accurate dosing. For anyone weighing both legality and safety, the prescription route is the one with actual legal and medical grounding behind it.
References
- Frier Levitt. “FDA Peptide Update 2026: Removal from ‘Do Not Compound’ List and What It Means for Pharmacies” (BPC-157 removed from Category 2 in April 2026; PCAC review July 23 to 24, 2026; removal is not approval).
- Vasireddi N, et al. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” HSS Journal. 2025 (mostly preclinical; no clinical safety data; no FDA-approved indication). https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
- USADA. “2026 WADA Prohibited List” (S2: peptide hormones, growth factors, and GH secretagogues prohibited in sport). https://www.usada.org/spirit-of-sport/2026-wada-prohibited-list/
- Lincoff AM, et al. “Cardiovascular Safety of Testosterone-Replacement Therapy” (TRAVERSE). N Engl J Med. 2023 (n=5,246; noninferior for MACE; more atrial fibrillation).
- “Glucagon-Like Peptide-1 Receptor Agonists.” StatPearls, NCBI Bookshelf (illustrating why prescription oversight and boxed-warning context matter for hormone and peptide therapies).
- Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006 (documents the GH-releasing peptide pharmacology referenced above).
